Amicus Therapeutics Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Here Are Amicus’s Key Research Programs in 2019

    Amicus Therapeutics is targeting a market opportunity worth more than $1.0 billion to $2.0 billion with its investigational AT-GAA ERT in the Pompe disease indication.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Is Amicus Therapeutics’ Galafold Placed in the First Quarter?

    According to the first-quarter earnings conference call, Amicus Therapeutics doesn’t expect linear revenue growth for Galafold on a quarter-over-quarter basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    FOLD and PTLA: What to Expect from Revenue Growth in Fiscal 2019

    Analysts expect Amicus Therapeutics’ revenues to rise YoY by 89.66% to $173.05 million in fiscal 2019.

    By Margaret Patrick
  • uploads///pills _
    Company & Industry Overviews

    What Are Analysts Recommending for FOLD and PTLA in May?

    Amicus Therapeutics and Portola Pharmaceuticals both have a consensus “buy” rating in May.

    By Margaret Patrick
  • uploads///SGMO net loss
    Company & Industry Overviews

    How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

    In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Jazz Pharmaceuticals: Analysts’ View in November

    On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.

    By Daniel Collins
  • uploads///headache _
    Company & Industry Overviews

    Analyzing PTC Therapeutics’ Performance in September

    On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.

    By Daniel Collins
  • uploads///Audentes ana reco
    Company & Industry Overviews

    Analyzing Audentes Therapeutics’ Valuation Metrics

    Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with $22.74 million in Q2 2017.

    By Kenneth Smith
  • uploads///capsule _
    Company & Industry Overviews

    How Analysts View Amicus Therapeutics in September

    Amicus Therapeutics (FOLD) plans to start the pivotal trial for AT-GAA in the second half of 2018.

    By Daniel Collins
  • uploads///Amicus
    Company & Industry Overviews

    Why Amicus Therapeutics Stock Rose Last Week

    Amicus Therapeutics (FOLD) saw a 19% rise in its stock in the week ended May 18.

    By Daniel Collins
  • uploads///FOLD
    Company & Industry Overviews

    Analyzing the Market Potential for Amicus’s Galafold

    According to Amicus Therapeutics, the annual incidence of the disease in newborn males is estimated to be between 1:40,000 and 1:60,000.

    By Kenneth Smith
  • uploads///FOLD
    Company & Industry Overviews

    Exploring Amicus Therapeutics’ Promising Research Pipeline

    Amicus Therapeutics’ most recent novel proprietary enzyme replacement therapy is currently in late preclinical development.

    By Kenneth Smith
  • uploads///mental health _
    Company & Industry Overviews

    Analysts Rate Voyager Therapeutics and Its Peers in April

    Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.

    By Kenneth Smith
  • uploads///Amicus
    Company & Industry Overviews

    Why Amicus Therapeutics Stock Rose in the Week Ended March 29

    On March 29, 2018, Amicus Therapeutics (FOLD) was trading at $15.04, which represented a ~135% rise from its 52-week low of $6.41.

    By Daniel Collins
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IBB Small-Caps Reduce Negative Returns in December

    The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.